银河磁体(300127.SZ):2名股东减持期届满 合计减持73.5万股
格隆汇1月6日丨银河磁体(300127.SZ)公布,2020年1月6日,公司收到了股东吴志坚、何金洲的《关于减持公司股份计划实施完毕的告知函》,此次股份减持计划实施的时间区间届满,两位股东此次减持计划实施完毕。股东吴志坚此次计划减持公司股份200万股,实际减持53.5万股;股东何金洲此次计划减持公司股份50万股,实际减持20万股;合计减持73.5万股。
此次减持后,吴志坚持有股份1152.23万股,占公司总股本的比例3.5657%;何金洲持有股份191.15万股,占公司总股本的比例0.5915%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.